Viropharma news from FierceBiotech
News
ViroPharma to buy Lev for $442M
Wyeth, ViroPharma drops Hep C drug
ALSO NOTED: Anemia drugs back in the spotlight; Biodel completes VIAject enrollment; and much more...
Wyeth stumbles badly trying to develop new drugs
ViroPharma, Wyeth halt HCV study
Four promising companies to watch
ALSO NOTED: Vasogen gets direction on Celacade: EndoCeutics pulls IPO; Ventana cool to bid; and much more...
> U.S. regulators have strongly suggested that Vasogen undertake a study to confirm the clinical data on Celacade before filing for approval of the heart medication. Report
> EndoCeutics has pulled its IPO, citing market conditions and a changeup in its schedule for clinical trials. The Canadian biotech is developing hormone therapies for breast cancer and endocrine-related disorders. …
Read more...C&L: Drakeman resigns from Medarex

Medarex CEO Donald Drakeman (photo) resigned his post as the company issued new findings in its investigation of how stock options were granted over the past 10 …
Read more...ALSO NOTED: Swiss approve Lucentis; ViroPharma shares buoyed by hep C data; and much more...
> Novartis has announced that Switzerland has approved Lucentis for age-related macular degeneration, marking its first European approval for the drug. The FDA approved Lucentis two months ago. Novartis says it will start supplying the drug in September. Report
> ViroPharma shares were buoyed by positive results from an early trial of its drug for hepatitis C. After 14 days of doses of HCV-796 …
Read more...SPOTLIGHT: Wyeth buying ViroPharma shares
Wyeth will buy $10 million in ViroPharma shares after the two collaborators achieved proof-of-concept stage for an experimental hepatitis C therapy. Preliminary data from Phase I should be available by the end of August. Report
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

